Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Where Will Bristol Myers Squibb Be in 5 Years?
Via The Motley Fool
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
Is Bristol Myers Squibb Stock a Buy?
Via The Motley Fool
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Via The Motley Fool
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases. 
Via Benzinga
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024. 
Via Talk Markets
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends. 
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans. 
Via Benzinga
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb. 
Via Investor's Business Daily
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders. 
Via Talk Markets
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet... 
Via Benzinga
Dow, S&P 500 On Track For Milestone Closes
Wall Street is extending its post-election rally into a new week. 
Via Talk Markets
Topics Stocks
Exposures US Equities
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline. 
Via Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company. 
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps. 
Via Benzinga
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies. 
Via Investor's Business Daily
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
Via Benzinga
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.